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THE ANTI-ATHEROGENIC POTENTIAL OF LIPOSOME-MEDIATED
DELIVERY OF LXR AGONISTS TO MACROPHAGES: A PRECLINICAL
VALIDATION STUDY
Menno Hoekstra, Janine J. Geerling, Wim Jiskoot, Miranda Van Eck. Leiden
Academic Centre for Drug Research, Leiden, Netherlands
Objective: Ligands for the nuclear receptor LXR increase the efflux of
cholesterol from macrophages and lower the susceptibility for athero-
sclerosis. To overcome the hepatic steatosis development associated with
systemic LXR agonism and facilitate clinical application of LXR agonists,
macrophage-specific LXR activation has to be achieved. Here we per-
formed a proof-of-principle study to show the anti-atherogenic potential
of liposome-mediated delivery of LXR agonists to macrophages.
Methods: The synthetic LXR agonist T0901317 was encapsulated into
cationic liposomes for use in vitro and in vivo studies.
Results: The ability of T0901317 to stimulate cholesterol efflux genes
ABCA1 and ABCG1 in vitro was maintained after encapsulation into lipo-
somes. Peritoneal injection of T0901317-loaded liposomes (5 mg/kg/day)
into hyperlipidemic apoE knockout mice for 4 days increased hepatic
expression levels of the macrophage-specific LXR target ABCG1 to an equal
extent as observed after standard oral dosing with 10mg/kg/day of the free
compound (2.8-fold versus 3.0-fold). In contrast, fatty acid synthase
expression was only 2.9-fold higher in T0901317 liposome-treated mice
versus 15-fold after oral treatment (P<0.001). Treatment of apoE knockout
mice with T0901317 liposomes for 8 weeks increased peritoneal cell
ABCA1 (2-fold; P<0.01) and ABCG1 (10-fold; P<0.001) expression levels.
Chronic T0901317 liposome treatment did e however e not alter the
susceptibility to atherosclerosis as judged from the similar aortic root
lesion size and aortic arch gene expression levels of the macrophage
marker CD68. Notably, peritoneal cell expression of the PXR target gene
CD36 was also >2-fold increased (P<0.001) in T0901317 liposome-treated
mice. It thus appears that the atheroprotective T0901317-induced increase
in macrophage cholesterol efflux may be nullified by the unwanted in-
crease in cholesterol influx associated with T0901317’s PXR agonisticaction.
Conclusions: In conclusion, our study is the first to show the improved 
clinical application potential of liposome-mediated delivery of LXR ago-
nists to macrophages over oral/systemic administration of these com-
pounds as the macrophage cholesterol efflux increasing effect is retained in 
the context of an elimination of the unwanted hepatocyte LXR-mediated 
metabolic effects.
